Cerecin, a Singapore-based biotech startup that focuses on neurotherapeutics, has raised $40 million in Series IIA funding round. Primarily backed by South Korean Investors, the round witnessed participation from SK Securities, Hana Financial Investment, Partners Investment, Arche Investment, K&T Investment, and many more. The firm plans on using these funds for research on Alzheimer’s disease, as well as to invest in product development and expand its pipeline.
_
This article has been summarised for quick read. The original article can be read on Deal Street Asia.